207 related articles for article (PubMed ID: 25208188)
1. Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties.
Kutoh E; Kaneoka N; Hirate M
Endocr Res; 2015; 40(2):88-96. PubMed ID: 25208188
[TBL] [Abstract][Full Text] [Related]
2. Distinct glucose-lowering properties in good responders treated with sitagliptin and alogliptin.
Kutoh E; Hirate M; Wada A
Int J Clin Pract; 2015 Nov; 69(11):1296-302. PubMed ID: 26194442
[TBL] [Abstract][Full Text] [Related]
3. Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial.
Kutoh E; Ukai Y
Endocrine; 2012 Jun; 41(3):435-41. PubMed ID: 22249941
[TBL] [Abstract][Full Text] [Related]
4. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.
Fujii Y; Abe M; Higuchi T; Mizuno M; Suzuki H; Matsumoto S; Ito M; Maruyama N; Okada K; Soma M
Expert Opin Pharmacother; 2013 Feb; 14(3):259-67. PubMed ID: 23289982
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes.
Liu X; Liu Y; Liu H; Li H; Yang J; Hu P; Xiao X; Liu D
Front Endocrinol (Lausanne); 2021; 12():694390. PubMed ID: 34616361
[TBL] [Abstract][Full Text] [Related]
6. Sitagliptin as an Initial Therapy and Differential Regulations of Metabolic Parameters Depending on its Glycemic Response in Subjects with Type 2 Diabetes.
Kutoh E; Kuto AN; Wada A; Hayashi J; Kurihara R
Drug Res (Stuttg); 2021 Mar; 71(3):157-165. PubMed ID: 33241550
[TBL] [Abstract][Full Text] [Related]
7. The Beneficial Effects of the DPP-4 Inhibitor Alogliptin on Hemoglobin A1c and Serum Lipids in Japanese Patients with Type 2 Diabetes.
Kusunoki M; Sato D; Nakamura T; Oshida Y; Tsutsui H; Natsume Y; Tsutsumi K; Miyata T
Drug Res (Stuttg); 2016 Jan; 66(1):18-22. PubMed ID: 26125284
[TBL] [Abstract][Full Text] [Related]
8. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
Jarvis CI; Cabrera A; Charron D
Ann Pharmacother; 2013 Nov; 47(11):1532-9. PubMed ID: 24285765
[TBL] [Abstract][Full Text] [Related]
9. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
Br J Pharmacol; 2009 Jun; 157(3):415-26. PubMed ID: 19371350
[TBL] [Abstract][Full Text] [Related]
10. Alogliptin: a DPP-4 inhibitor modulating adipose tissue insulin resistance and atherogenic lipid.
Kutoh E; Kuto AN; Akiyama M; Ozawa E; Kurihara R
Eur J Clin Pharmacol; 2023 Jul; 79(7):947-959. PubMed ID: 37193913
[TBL] [Abstract][Full Text] [Related]
11. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.
Pratley RE; McCall T; Fleck PR; Wilson CA; Mekki Q
J Am Geriatr Soc; 2009 Nov; 57(11):2011-9. PubMed ID: 19793357
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
Covington P; Christopher R; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
Clin Ther; 2008 Mar; 30(3):499-512. PubMed ID: 18405788
[TBL] [Abstract][Full Text] [Related]
13. Alogliptin: safety, efficacy, and clinical implications.
Marino AB; Cole SW
J Pharm Pract; 2015 Feb; 28(1):99-106. PubMed ID: 24532820
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Pratley RE; Reusch JE; Fleck PR; Wilson CA; Mekki Q;
Curr Med Res Opin; 2009 Oct; 25(10):2361-71. PubMed ID: 19650752
[TBL] [Abstract][Full Text] [Related]
15. Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
Ndefo UA; Okoli O; Erowele G
Am J Health Syst Pharm; 2014 Jan; 71(2):103-9. PubMed ID: 24375601
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
Capuano A; Sportiello L; Maiorino MI; Rossi F; Giugliano D; Esposito K
Drug Des Devel Ther; 2013; 7():989-1001. PubMed ID: 24068868
[TBL] [Abstract][Full Text] [Related]
17. Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes.
Takebayashi K; Sakurai S; Suzuki T; Hori K; Terasawa T; Naruse R; Hara K; Suetsugu M; Tsuchiya T; Aoki H; Hamasaki T; Shuutou H; Inukai T
Endocr J; 2014; 61(10):1031-9. PubMed ID: 25185672
[TBL] [Abstract][Full Text] [Related]
18. Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus.
Kishimoto S; Kinoshita Y; Matsumoto T; Maruhashi T; Kajikawa M; Matsui S; Hashimoto H; Takaeko Y; Kihara Y; Chayama K; Goto C; Mohamad Yusoff F; Nakashima A; Noma K; Higashi Y
Am J Hypertens; 2019 Jun; 32(7):695-702. PubMed ID: 31045223
[TBL] [Abstract][Full Text] [Related]
19. A Randomized Pilot Study of the Effect of Trelagliptin and Alogliptin on Glycemic Variability in Patients with Type 2 Diabetes.
Nishimura R; Osonoi T; Koike Y; Miyata K; Shimasaki Y
Adv Ther; 2019 Nov; 36(11):3096-3109. PubMed ID: 31562608
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial.
Ji L; Li L; Kuang J; Yang T; Kim DJ; Kadir AA; Huang CN; Lee D
Diabetes Obes Metab; 2017 May; 19(5):754-758. PubMed ID: 28075066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
